Quanterix Corporation $QTRX Stock Holdings Decreased by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. lessened its position in Quanterix Corporation (NASDAQ:QTRX) by 53.7% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 231,601 shares of the company’s stock after selling 268,797 shares during the quarter. Envestnet Asset Management Inc. owned approximately 0.46% of Quanterix worth $1,540,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. William Blair Investment Management LLC raised its stake in Quanterix by 2.0% during the 2nd quarter. William Blair Investment Management LLC now owns 1,127,981 shares of the company’s stock valued at $7,501,000 after purchasing an additional 21,918 shares during the period. Vanguard Personalized Indexing Management LLC boosted its position in shares of Quanterix by 40.5% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 15,024 shares of the company’s stock worth $100,000 after buying an additional 4,330 shares during the period. Aberdeen Group plc grew its holdings in shares of Quanterix by 56.6% during the second quarter. Aberdeen Group plc now owns 420,856 shares of the company’s stock valued at $2,799,000 after buying an additional 152,139 shares in the last quarter. Peddock Capital Advisors LLC acquired a new position in Quanterix during the second quarter valued at $117,000. Finally, Jane Street Group LLC raised its position in Quanterix by 4.2% during the first quarter. Jane Street Group LLC now owns 58,313 shares of the company’s stock valued at $380,000 after buying an additional 2,366 shares during the period. Institutional investors and hedge funds own 86.48% of the company’s stock.

Quanterix Price Performance

Shares of NASDAQ QTRX opened at $5.86 on Thursday. Quanterix Corporation has a one year low of $4.05 and a one year high of $13.01. The business’s 50-day moving average price is $5.48 and its two-hundred day moving average price is $5.46. The company has a market capitalization of $273.72 million, a P/E ratio of -2.52 and a beta of 1.12.

Quanterix (NASDAQ:QTRX) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.13). The firm had revenue of $40.23 million for the quarter, compared to analysts’ expectations of $37.85 million. Quanterix had a negative return on equity of 21.34% and a negative net margin of 73.47%. Quanterix has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that Quanterix Corporation will post -0.98 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Canaccord Genuity Group restated a “hold” rating and set a $5.00 price objective (down from $12.00) on shares of Quanterix in a research report on Monday, August 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Quanterix in a report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $10.33.

About Quanterix

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.